View Older Stories View More Recent Stories

Mar 30, 2021 06:15PM Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
Mar 22, 2021 04:05PM Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum
Mar 18, 2021 07:45AM Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia
Feb 23, 2021 04:10PM Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference
Feb 23, 2021 04:05PM Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results
Feb 17, 2021 04:05PM Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference
Feb 16, 2021 07:46AM Jazz Pharmaceuticals (JAZZ) Completes Submission of sNDA for Xywav Oral Solution for Idiopathic Hypersomnia
Feb 16, 2021 07:45AM Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
Feb 9, 2021 04:05PM Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021
Feb 3, 2021 07:31AM Jazz Pharmaceuticals (JAZZ) to Acquire GW Pharmaceuticals (GWPH) for $220/sh in $7.2 Billion Deal
Feb 3, 2021 07:30AM Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
Jan 4, 2021 04:05PM Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference
Dec 21, 2020 08:07AM Jazz Pharmaceuticals (JAZZ) Announces Initiation of BLA Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Dec 21, 2020 08:00AM Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Dec 3, 2020 06:12AM Jazz (JAZZ), PharmaMar ATLANTIS Phase 3 Study Evaluating Zepzelca in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line Did Not Meet Pri
Dec 3, 2020 02:00AM Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platin
Nov 17, 2020 07:30AM Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors
Nov 10, 2020 04:05PM Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference
Nov 5, 2020 07:30AM Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research
Nov 2, 2020 04:05PM Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results
Oct 26, 2020 07:31AM Jazz Pharmaceuticals (JAZZ) Acquires SpringWorks Therapeutics' (SWTX) FAAH Inhibitor Program
Oct 26, 2020 07:30AM Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Oct 20, 2020 07:34AM Jazz Pharmaceuticals (JAZZ) Announces SLEEP Publication of Phase 3 Xywav Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy
Oct 20, 2020 07:30AM Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients w
Oct 19, 2020 04:15PM Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update
Oct 19, 2020 04:05PM Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020
Oct 14, 2020 04:05PM New Data for Zepzelca™ (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer
Oct 8, 2020 07:33AM Jazz Pharmaceuticals (JAZZ) Announces Positive Top-line Results from Phase 3 Study of Xywav Oral Solution in Adult Patients with Idiopathic Hypersomnia
Oct 8, 2020 07:30AM Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia
Sep 17, 2020 07:00AM Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia
Sep 15, 2020 08:00AM Jazz Pharmaceuticals Announces New Sleep Health Collaboration
Sep 14, 2020 07:30AM Acerus Announces Addition of US Commercial Leader
Sep 9, 2020 07:31AM Jazz Pharmaceuticals (JAZZ) Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies
Sep 9, 2020 07:30AM Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies
Sep 8, 2020 04:05PM Jazz Pharmaceuticals Announces Participation at Three Upcoming Virtual Investor Conferences
Aug 27, 2020 08:00AM Jazz Pharmaceuticals to Present New Data on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Sunosi® (solriamfetol) at Virtual SLEEP 2020
Aug 4, 2020 04:05PM Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results
Jul 22, 2020 07:32AM Jazz Pharmaceuticals (JAZZ) Announces U.S. FDA Approval of Xywav Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Jul 22, 2020 07:30AM Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Jul 21, 2020 04:05PM Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020
Jul 13, 2020 08:00AM National Comprehensive Cancer Network® adds Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology
Jun 15, 2020 03:36PM Jazz Pharmaceuticals (JAZZ) Announces U.S. FDA Accelerated Approval of Zepzelca for Treatment of Metastatic Small Cell Lung Cancer
Jun 15, 2020 03:35PM Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
May 27, 2020 04:05PM Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
May 14, 2020 09:53AM Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
May 11, 2020 08:30AM Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America
May 6, 2020 04:05PM Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences
May 5, 2020 04:05PM Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results
Apr 29, 2020 04:10PM Jazz Pharmaceuticals (JAZZ) Stops Enrollment in Phase 3 Study of Defibrotide as its 'Highly Unlikely' to Reach Statistical Significance
Apr 29, 2020 04:05PM Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
View More Recent Stories View Older Stories